Platelet Glycoprotein IIb/IIIa Receptor Blockade: Lessening the Risk of Coronary Interventions

Summary

For the patient undergoing percutaneous coronary intervention, the administration of a platelet glycoprotein IIb/IIIa receptor blocker reduces the incidence of a periprocedural nonfatal myocardial infarction and the need for unplanned emergency stenting. In the diabetic patient undergoing intracoronary stenting, the use of a platelet glycoprotein IIb/IIIa receptor blocker appears to decrease the need for subsequent target vessel revascularization. There is considerable evidence in support of the use of glycoprotein IIb/IIIa receptor inhibitors in all categories of patients – “high-risk” patients, “low-risk” patients, and those undergoing primary angioplasty for acute myocardial infarction – and for the full armamentarium of percutaneous procedures (angioplasty, directional atherectomy, rotational atherectomy, and intracoronary stenting).

Key words

Glycoprotein IIb/IIIa - PTCA - stent - platelets

• References

• 1 Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994; 330: 981-93.
• 2 Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-8.
• 3 Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997; 96: 1445-53.
• 4 Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-43.
• 5 Kong DF, Califf RM, Miller DP. et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35.
• 6 Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998; 98: 1802-20.
• 7 EPIC. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation N Engl J Med 1994; 330: 956-61.
• 8 Topol EJ, Ferguson JJ, Weisman HF. et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 479-84.
• 9 Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
• 10 Ellis SG, Serruys PW, Popma JJ. et al. Can abciximab prevent neointimal proliferation in Palmz-Schatz stents?. Circulation 1997; 96 (Suppl I) I-87.
• 11 Brener SJ, Barr LA, Burchenal JE. et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-41.
• 12 Kleiman NS, Lincoff AM, Kereiakes DJ. et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998; 97: 1912-20.
• 13 Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
• 14 Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. N Engl J Med 1998; 338: 1488-97.
• 15 Investigators TTI. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89: 1545-56.
• 16 Thel MC, Califf RM, Tcheng JE. et al. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. Am Heart J 1999; 137: 264-73.
• 17 Lefkovits J, Blankenship JC, Anderson KM. et al. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. J Am Coll Cardiol 1996; 28: 849-55.
• 18 Ghaffari S, Kereiakes DJ, Lincoff AM. et al. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. Am J Cardiol 1998; 82: 7-12.
• 19 Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). Circulation 1998; 98: 742-8.
• 20 Rawitscher D, Levin TN, Cohen I, Feldman T. Rapid reversal of no-reflow using Abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 42: 187-90.
• 21 Koch KC, vom Dahl J, Kleinhans E. et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol 1999; 33: 998-1004.
• 22 Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.